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Diabetes, atherosclerosis, hypertension and stroke are common comorbidities and the 
leading causes of death and disability worldwide. Current therapies are symptom-
oriented, do not target the underlying cause and are therefore imprecise. One main 
reason for this unmet medical need is that these complex diseases are defined by a 
symptom in an organ and not by a molecular mechanism. Network medicine, however, 
shows that within the diseasome these comorbidites relate to the same cluster and, 
thus, likely share common hidden causal pathomechanisms. Targeting these 
mechanisms would be prefered to syptomatic therapy and, sicne these mechanisms are 
small signalling modules, network pharmacology is preferable to single-target 
approaches. One example of such a causal signalling module is the reactive oxygen 
species (ROS) and cGMP signaling (ROCG) network. 
Pharmacologically, several drug classes target this network, including  NADPH oxidase 
(NOX) inhibitors and nitric oxide (NO) donors. In this thesis, a NOX inhibitor panel 
approach was successfully applied to pharmacologically validate the pathomechanistc 
involvement of a specific NOX isoform. In addition, NO-cGMP signalling was found to 
be halted by chronic elevation of NO as part of a chemical feedback loop that converts 
the NO receptor, soluble guanylate cyclase (sGC), to the heme-free and NO-insensitive 
apo-sGC. Therefore, other drug classess such as sGC stimulators and apo-sGC activators 
will be superior to NO donors for chronic use.  
In a comorbidity model of stroke plus diabetes, a network pharmacology approach using 
subthreshold doses of a NOX and an NO synthase (NOS) inhibitor plus apo-sGC 
activator, resulted in a substantial neuroprotective effect. This approach is now in 
clinical trials. Also in diabetes, NADPH oxidase 5 (NOX5) was found as the most direct 
neighbour to NO-cGMP-related proteins. This connection was functionally validated 
both in a subgroup of hypertensive patients and in NOX5-knock in mice where NOX5 
induced NOS uncoupling as a causal mechanism to induce age-related hypertension. 
Collectively, network pharmacology targeting causal disease modules represents a new 
approach to precisely define, diagnose and cure hitherto complex comorbidities such as 
diabetes, atherosclerosis, hypertension and stroke. Further validations in clinical trials 
is needed and planned to start in late 2020. 
  
